JPM 2026

Event description:

Biotech moves fast. Your CRO should too. Meet Novotech at JPM 2026. Decisions made in San Francisco will shape the next 12–24 months. Novotech partners with biotechs at every phase to start smarter, move faster, and scale globally with confidence, combining accelerated first-in-human pathways with high-performing regions across APAC, North America, and Europe to stretch capital, reduce uncertainty, and reach meaningful data sooner.

With 4,450+ clinical trials delivered across Phases I–IV, 7,260+ sites initiated, partnerships with 4950+ investigators, across 50+ countries worldwide, we connect the world’s most effective clinical environments into one integrated development pathway.

• Early-phase acceleration in Australia (FIH pathways, seasoned start-up teams).
• Scalable recruitment across APAC (including China) with strong local operations.
• Integrated execution in the U.S. and Europe (regulatory, clinical operations, biostatistics, project leadership).

Don’t miss these events:

Mon, Jan. 12: The Fast Lane to PoC: Leveraging Australia and China for Smarter Early Clinical Development during RESI, 10:00–10:50 a.m., Marriott Marquis.

Tues, Jan. 13: Dr. Judith Ng-Cashin joins the Fierce JPM Week panel Next-Gen Partnerships: Unlocking Speed, Scale, and Value in Clinical Development, 11:00–11:40 a.m., Hyatt Embarcadero.

If you’ll be in San Francisco, we’d welcome a conversation about timelines, regional strategy, and your next milestone. Please request a meeting via the form on this page.

Meet Our Team:

• Dr. Judith Ng-Cashin — Chief Medical Officer
• Barry Murphy — Chief Commercial Officer
• Dr. Yooni Kim — Chief Product Officer
• Michael Stibilj — Chief Operating Officer
• Rick Farris — Managing Director, North America
• Andy Liu — Managing Director, China
• David Ng — VP, Biometrics

Plus commercial and clinical teams from North America, Europe, and APAC.